Crossmark

Indirect inhibition of the NLRP3-interleukin-1β axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitis

Crossref DOI link: https://doi.org/10.1038/s41467-026-71808-y

Published Online: 2026-04-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Beibei https://orcid.org/0009-0008-5596-0355
Spalinger, Marianne R. https://orcid.org/0000-0003-4498-0058
Invernizzi, Annalisa https://orcid.org/0009-0000-3380-8602
Gerdes, Eike

Steglich, Babett

Schwarzfischer, Marlene

Machicote, Andres

Pelczar, Penelope

Pöhlmann, Doris

Nawrocki, Mikolaj

Böttcher, Marius

Aleko, Ayob

Velasquez, Lis Noelia

Wende, Sandra

Stallbaum, Franziska

Neuendorff, Justus

Grosshauser, Saskia

Muscate, Franziska https://orcid.org/0009-0003-4639-4594
Douilhet, Gemma

Perez, Laura Garcia

Sabihi, Morsal

Möller, Katharina

Viehweger, Florian

Sutter, Jan P.

Kilian, Christoph

Kumar, Yogesh

Fründt, Thorben

Sauter, Guido

Rösch, Thomas

Gagliani, Nicola https://orcid.org/0000-0001-8514-1395
Caflisch, Amedeo https://orcid.org/0000-0002-2317-6792
Scharl, Michael https://orcid.org/0000-0002-6729-1469
Huber, Samuel https://orcid.org/0000-0001-9325-8227
License Information

Text and Data Mining valid from 2026-04-18

Accepted Manuscript valid from 2026-04-18
More Information

Article History

Received: 2 January 2024

Accepted: 30 March 2026

First Online: 18 April 2026

Competing interests

: M.S. has shares and is co-founder of Recolony AG, Zurich, CH and has shares in PharmaBiome AG, Zurich, CH. M.S. served as Advisor for Abbvie, Gilead, Fresenius, Topadur, Takeda, Roche and Celltrion. M.S. received speaker’s honoraria from Janssen, Falk Pharma, Vifor Pharma, Pileje and Bromatech. M.S. received research grants from Abbvie, Takeda, Gilead, Gnubiotics, Roche, Axalbion, Pharmabiome, Topadur, Basilea, MBiomics, Storm Therapeutics, LimmatTech, Zealand Pharma, NodThera, Calypso Biotech, Pileje, Herbodee, Vifor. S.H. served as Advisor for Abbvie and Janssen. S.H. received speaker’s honoraria from Abbvie, Janssen, Falk Pharma, Ferring, Galapagos. S.H. received an Ecco-Pfizer research grant. N.G. reports financial support from F. Hoffmann–La Roche and from GlaxoSmithKline (GSK); the support from GSK is for work unrelated to the topic of this manuscript. All support is administered via UKE. The remaining authors declare no competing interests

Document is current

Any future updates will be listed below